Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

Prior treatment

• Any previous treatment with anti-CD20, eculizumab, anti-BLyS monoclonal antibody (e.g., belimumab), any other treatment for prevention of multiple sclerosis (MS) relapse (e.g., interferon, natalizumab, glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate) within 6 months prior to baseline.
• Received immunosuppression such as azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide, tacrolimus, mitoxantrone, cyclosporine A, etc, and rug therapy, biological agents such as satralizumab, tocilizumab, eculizumab, etc, 3 months prior to the first administration.
• Evidence of serious uncontrolled concomitant diseases that may preclude participant participation, as described; Other nervous system disease, cardiovascular disease, hematologic/hematopoiesis disease, respiratory disease, muscular disease, endocrine disease, renal/urologic disease, digestive system disease, congenital or acquired severe immunodeficiency.
• Known active infection within 3 months prior to baseline
• History of drug or alcohol abuse within 6 months prior to baseline
• Receipt of any live or live attenuated vaccine within 4 weeks prior to baseline

Other illness

• History of severe allergic reaction to a biologic agent
• Evidence of chronic active hepatitis B or C
• Evidence of active tuberculosis
• Uncontrolled systemic diseases, including hypertension that cannot be effectively controlled after treatment (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg), diabetes, gastrointestinal diseases, etc.; or the investigator believes that there is anything inappropriate reasons for selection.

Lab values

• Following laboratory abnormalities at screening\*:
  • White blood cells (WBC) \<4.0 x10\^3/microliter (μL)
  • Absolute neutrophil count (ANC)
  • Absolute lymphocyte count \<0.5 x10\^3/μL
  • Platelet count \<80 x 10\^9/ L
  • Aspartate aminotransferase (AST) or alanine aminotransferase

Other

• Pregnancy or lactation.

• NMOSD as defined by either of the following 2015 criteria with anti-AQP4 antibody (Ab) seropositive status at screening
• Clinical evidence of at least 1 documented relapse in last 12 months prior to screening
• Expanded Disability Status Scale (EDSS) score from 0 to 7.5 inclusive at screening
• Age 18 to 70 years, inclusive at the time of informed consent